Meeting
2020 ASCO Virtual Scientific Program
ONC201 in previously irradiated pediatric H3 K27M-mutant glioma or newly diagnosed DIPG.
Authors
Sharon L. Gardner
New York University School of Medicine, New York, NY
Sharon L. Gardner , Carl Johannes Koschmann , Rohinton Tarapore , Jeffrey C. Allen , Wafik Tharwat Zaky , Yazmin Odia , Matthew Hall , Doured Daghistani , Ziad Khatib , Dolly Aguilera , Tobey J. MacDonald , Maryam Fouladi , Susan Lynne McGovern , Cassie Kline , Nicholas A Vitanza , Guangrong Lu , Wolfgang Oster , Joshua E. Allen , Soumen Khatua
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT03416530
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3619)
DOI
10.1200/JCO.2020.38.15_suppl.3619
Abstract #
3619
Poster Bd #
349
Abstract Disclosures
Similar Posters
First Author: Sharon L. Gardner
Poster
2020 ASCO Virtual Scientific Program
Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma.
First Author: Sylvia Christine Kurz
Poster
2023 ASCO Annual Meeting
Phase 1/2, first-in-child study of sonodynamic therapy (SDT) using low intensity focused ultrasound and 5-aminolevulinic acid (ALA) for patients with diffuse intrinsic pontine glioma.
First Author: Hasan R Syed
Poster
2020 ASCO Virtual Scientific Program
Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma.
First Author: Isabel Arrillaga-Romany